肽聚糖水解酶RipA对结核分枝杆菌北京暴发菌株的免疫原性与保护效力
研究以潜伏感染相关抗原RipA作为结核亚单位疫苗候选,发现RipA可激活树突状细胞并促进Th1极化免疫应答,RipA/GLA-SE免疫小鼠在两种北京临床菌株气溶胶攻击下介导的保护效果作为单一抗原不劣于BCG。
要点
- RipA通过诱导表型成熟、增加炎性细胞因子及激活MAPK和NF-κB信号通路激活树突状细胞。
- RipA处理的树突状细胞促进初始CD4+ T细胞Th1极化并增强对巨噬细胞内分枝杆菌生长的控制。
- RipA/GLA-SE免疫小鼠在常规或超低剂量气溶胶攻击下作为单一抗原保护效果不劣于BCG。
核心结论
- RipA可作为多抗原结核亚单位疫苗组分的新候选。
研究设计与样本
- 研究为实验性疫苗免疫原性与保护效力评价,使用RipA蛋白及GLA-SE佐剂免疫小鼠,并以2株结核分枝杆菌北京临床菌株进行常规或超低剂量气溶胶攻击。
主要发现
- RipA诱导树突状细胞表型成熟、增加炎性细胞因子产生并激活MAPK和NF-κB信号通路。
- RipA处理的树突状细胞促进初始CD4+ T细胞增殖和Th1极化,并激活结核分枝杆菌感染小鼠的T细胞,增强巨噬细胞内分枝杆菌生长控制。
- RipA/GLA-SE免疫小鼠肺和脾中产生抗原特异性多功能CD4+ T细胞。
- 对2株结核分枝杆菌北京临床菌株的常规或超低剂量气溶胶攻击,RipA/GLA-SE作为单一抗原介导的保护效果不劣于BCG。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given that individuals with latent tuberculosis (TB) infection represent the major reservoir of TB infection, latency-associated antigens may be promising options for development of improved multi-antigenic TB subunit vaccine. Thus, we selected RipA, a peptidoglycan hydrolase required for efficient cell division of Mycobacterium tuberculosis (Mtb), as vaccine candidate. We found that RipA elicited activation of dendritic cells (DCs) by induction of phenotypic maturation, increased production of inflammatory cytokines, and prompt stimulation of MAPK and NF-κB signaling pathways. In addition, RipA-treated DCs promoted Th1-polarzied immune responses of naïve CD4+ T cells with increased proliferation and activated T cells from Mtb-infected mice, which conferred enhanced control of mycobacterial growth inside macrophages. Moreover, mice immunized with RipA formulated in GLA-SE adjuvant displayed remarkable generation of Ag-specific polyfunctional CD4+ T cells in both lung and spleen. Following an either conventional or ultra-low dose aerosol challenges with 2 Mtb Beijing clinical strains, RipA/GLA-SE-immunization was not inferior to BCG by mediating protection as single Ag. Collectively, our findings highlighted that RipA could be a novel candidate as a component of multi-antigenic TB subunit vaccines.
引用
- Kwon KW, Choi HG, Choi HH, et al. Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains. Vaccine. 2024. PMID: 38368223. doi:10.1016/j.vaccine.2024.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。